title: Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats.
abstract: The potent and selective phosphodiesterase 4 inhibitor ASP3258 is a novel therapeutic agent for asthma and chronic obstructive pulmonary disease (COPD). After a single oral administration to rats, ASP3258 is rapidly absorbed with a bioavailability of 106%. In situ absorption data indicated that ASP3258 is mainly absorbed in the small intestine. Tissue distribution data after oral administration of (14)C-ASP3258 showed rapid and extensive distribution to various tissues. Excluding the gastrointestinal tract, the tissues with the highest concentrations were liver, heart and plasma. Liquid chromatography-nuclear magnetic resonance spectroscopy data revealed that O-glucuronidation of the carboxylic acid moiety of ASP3258 (formation of an acyl glucuronide) plays a key role in metabolism. No indication was found that the acyl glucuronide reacted with proteins in plasma or tissues. When (14)C-ASP3258 was orally administered to intact rats, urinary and fecal excretion accounted for 1.3% and 100.6% of the administered radioactivity, respectively. After a single oral administration of (14)C-ASP3258 to bile-cannulated rats, urinary and biliary excretion accounted for 0.7% and 93.8% of the administered radioactivity, respectively. These findings suggest that fecal excretion via bile plays an important role in the elimination of ASP3258-derived radioactivity. In vitro metabolic profiles were relatively similar among the species examined, suggesting that our findings in rats may help us to understand pharmacokinetics, efficacy and safety profiles in humans and other species.
authors.affiliation: Analysis and Pharmacokinetics Research Laboratories, Astellas Pharma Inc., Osaka, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ohtsu
authors.forename: Takuya
authors.initials: T
authors.lastname: Sonoda
authors.forename: Yoko
authors.initials: Y
authors.lastname: Susaki
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Tohda
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Fukunaga
authors.forename: Takafumi
authors.initials: T
authors.lastname: Iwatsubo
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Noguchi
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001646:Bile / Q000378:metabolism*; D001682:Biological Availability; D002853:Chromatography, Liquid; D007408:Intestinal Absorption; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009287:Naphthyridines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D058988:Phosphodiesterase 4 Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D011916:Rats, Inbred F344; D014018:Tissue Distribution
chemical_list: C561429:3-(4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl)propanoic acid; D009287:Naphthyridines; D058988:Phosphodiesterase 4 Inhibitors
keywords: ASP3258; LC/NMR; acyl glucuronide; radioactivity; rats